Home
Resource
A robust paradigm of finding the maximum tolerated dose in phase I cancer clinical trials with application to IL-21 denenicokin
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(1.65 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Young, Tina Chang. A robust paradigm of finding the maximum tolerated dose in phase I cancer clinical trials with application to IL-21 denenicokin. Retrieved from https://doi.org/doi:10.7282/T3KW5JZD

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleA robust paradigm of finding the maximum tolerated dose in phase I cancer clinical trials with application to IL-21 denenicokin
NameYoung, Tina Chang (author); Shih, Weichung Joe (chair); LIN, YONG (internal member); Moore, Dirk F (internal member); Simonsen, Katy L (outside member); Rutgers University; School of Public Health
Date Created2017
Other Date2017-05 (degree)
SubjectPublic Health, Clinical trials--Design, Cancer--Treatment
Extent1 online resource (xiv, 145 p. : ill.)
DescriptionIn Phase I oncology trials, the main objective is typically to determine the maximum tolerated dose (MTD), the highest dose of a drug that does not cause unacceptable side effects. The MTD is determined by testing increasing doses on patient cohorts until the highest dose with acceptable side effects is found. To determine the MTD, many different dose escalation designs have been developed, such as the CRM, BLRM, mTPI-2, and BOIN, each of which has improved statistical properties over the traditional A+B class of designs. Yet most published Phase I trials still use a traditional 3+3 design. This dissertation proposes a robust paradigm of conducting Phase I cancer clinical trials that involves simultaneously running multiple designs to obtain a robust MTD. This paradigm will provide more confidence to clinicians and regulators in the selection of the dose for further drug development. The implementation of this paradigm with an application to the IL-21 denenicokin clinical development program is the focus of this dissertation.
NoteDr.P.H.
NoteIncludes bibliographical references
Noteby Tina Chang Young
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T3KW5JZD
Languageeng
CollectionSchool of Public Health ETD Collection
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024